Location History:
- Rehovot, IL (1998 - 2024)
- Tel Yitzhak, IL (2024)
Company Filing History:
12 out of 1,168 
2 out of 893 
2 out of 48 
Years Active: 1998-2024
Title: **Zelig Eshhar: Pioneering Innovations in Cancer Immunotherapy**
Introduction
Zelig Eshhar is a prominent inventor based in Rehovot, Israel, known for his groundbreaking contributions to the field of cancer immunotherapy. With a remarkable portfolio of 13 patents, he has been at the forefront of developing novel T-cell therapies aimed at treating various forms of cancer.
Latest Patents
Among his latest innovative patents is one that involves T-cells modified to express two different chimeric antigen receptors (CARs). This invention specifically addresses T-cells that express one CAR binding to antigens such as CD138, HER2, or CD24, while another CAR binds to a different antigen from the same set. By utilizing these CAR T-cells in pharmaceutical compositions, the approach demonstrates significant promise for cancer treatment, particularly ovarian cancer.
Another noteworthy patent by Eshhar covers T-cells that express both anti-CD38 and anti-CD138 chimeric antigen receptors. This patent elaborates on T-cells designed to express two distinct CARs, facilitating treatment strategies for multiple myeloma and highlighting methods for the preparation of these advanced therapeutic cells.
Career Highlights
Zelig Eshhar's career is marked by his essential roles in esteemed organizations like Yeda Research and Development Company Ltd. and Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Throughout his career, he has been dedicated to pioneering research in cellular immunotherapy, shaping the future of cancer treatments.
Collaborations
Eshhar has had the opportunity to work alongside distinguished colleagues, including Tova Waks and Gideon Gross. These collaborative efforts have fostered an environment of innovation and inquiry, leading to significant advancements in the field of chimeric antigen receptor therapy.
Conclusion
In conclusion, Zelig Eshhar's innovative work in developing CAR T-cells has set a benchmark in the fight against cancer. His patents not only reflect his expertise and dedication but also hold the potential to transform therapeutic strategies for patients worldwide. Through his continued efforts in research and collaboration, he remains a vital contributor to advancements in medical science and cancer treatment.